Danielle Brill
Stock Analyst at Raymond James
(1.89)
# 2,937
Out of 4,827 analysts
75
Total ratings
34.38%
Success rate
-8.45%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $10.08 | +415.87% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $18.91 | +243.82% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.26 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $59.29 | +33.24% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $7.27 | +147.59% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $121.51 | +27.56% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $13.88 | +159.37% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $33.49 | +19.44% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $36.68 | +308.94% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $117.21 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.83 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $434.82 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $622.64 | -2.83% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.79 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $35.33 | +41.52% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $28.16 | +81.11% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $43.54 | -1.23% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.34 | +1,359.85% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $40.73 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.33 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $10.08
Upside: +415.87%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $18.91
Upside: +243.82%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.26
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $59.29
Upside: +33.24%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.27
Upside: +147.59%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $121.51
Upside: +27.56%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $13.88
Upside: +159.37%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $33.49
Upside: +19.44%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $36.68
Upside: +308.94%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $117.21
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $6.83
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $434.82
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $622.64
Upside: -2.83%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.79
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $35.33
Upside: +41.52%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $28.16
Upside: +81.11%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $43.54
Upside: -1.23%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.34
Upside: +1,359.85%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $40.73
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.33
Upside: -